NCT04566393 2026-06-04Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered MalignanciesxCuresAvailable
NCT06872489 2025-07-23Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid TumorsSecond Life TherapeuticsAvailable